FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2414893599> ?p ?o ?g. }

• W2414893599 endingPage "ix125" @default.
• W2414893599 startingPage "ix125" @default.
• W2414893599 abstract "Aim/Background: Growing number of patients with EGFR activating mutation (EGFR M+) treated with EGFR-TKIs (tyrosine kinase inhibitors) suffer from metastases to central nervous system (CNS). This is because the prognosis of patient with EGFR M+ has substantially prolonged by EGFR-TKIs, but efficacy of EGFR-TKIs in CNS lesion is relatively low. By using Matrix Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry imaging (MSI) and liquid chromatography-tandem mass spectrometry (LC-MS/MS), we analyzed whether erlotinib is penetrating to CNS. Methods: Autopsy specimens from a patient with EGFR M+ who was taking erlotinib for two months were analyzed. On suspicion of leptomeningeal metastasis, patient was taking erlotinib even after the radiological progression in thoracic lesion until 48 hours before death. iMScope (Shimadzu, Japan) was used for IMS, and the concentrations of erlotinib in specimens were validated using LC-MS/MS. Results: Autopsy survey found no leptomeningeal metastasis. MSI showed erlotinib distribution to normal tissue and tumor lesion but not to brain specimens. Concentration of erlotinib (ng/mm2) in normal lung tissue, pulmonary metastases with lymphangitis carcinomatosis, pleural dissemination, medulla oblongata, cerebellum, and cerebrum was 12.0, 11.8, 12.5, 2.8, 1.4 and 1.7, respectively. Concentration of cerebrospinal fluid was 96.4 ng/mL, which is slightly higher than the previous reports probably due to the trace contamination of blood during the procedure of collection. Conclusions: Although erlotinib concentration in normal and cancer lesion was biologically enough, concentration to CNS lesion was fairly low. Penetration to cerebrospinal fluid did not correlate with distribution of erlotinib to brain parenchyma. These results may suggest that the efficacy of erlotinib to CNS metastasis is achieved by the destruction of blood brain barrier and penetration to the cancer lesion. Whether better control of CNS metastasis will be achieved by penetration to CNS parenchyma or only to the cancer lesion is an interesting debate for the future development of TKIs. Disclosure: Y. Goto: membership on an advisory board or board of directors Lilly, Boehringer Ingelheim, Taiho A. Hamada: corporate-sponsored research from Chugai. Y. Ohe: membership on an advisory board or board of directors Chugai, AstraZeneca, Lilly, Boehringer Ingelheim, Novartis, ONO, BMS. All other authors have declared no conflicts of interest." @default.
• W2414893599 created "2016-06-24" @default.
• W2414893599 creator A5003341249 @default.
• W2414893599 creator A5003772441 @default.
• W2414893599 creator A5008127698 @default.
• W2414893599 creator A5017999352 @default.
• W2414893599 creator A5021958776 @default.
• W2414893599 creator A5024939717 @default.
• W2414893599 creator A5030587345 @default.
• W2414893599 creator A5039554579 @default.
• W2414893599 creator A5049404391 @default.
• W2414893599 creator A5060510665 @default.
• W2414893599 creator A5077450352 @default.
• W2414893599 creator A5084095032 @default.
• W2414893599 date "2015-12-01" @default.
• W2414893599 modified "2023-10-16" @default.
• W2414893599 title "449P Distribution of erlotinib to brain, tumor lesion and normal tissue analyzed by matrix assisted laser desorption/ionization mass spectrometry imaging and liquid chromatography-tandem mass spectrometry" @default.
• W2414893599 doi "https://doi.org/10.1093/annonc/mdv532.33" @default.
• W2414893599 hasPublicationYear "2015" @default.
• W2414893599 type Work @default.
• W2414893599 sameAs 2414893599 @default.
• W2414893599 citedByCount "2" @default.
• W2414893599 countsByYear W24148935992021 @default.
• W2414893599 countsByYear W24148935992022 @default.
• W2414893599 crossrefType "journal-article" @default.
• W2414893599 hasAuthorship W2414893599A5003341249 @default.
• W2414893599 hasAuthorship W2414893599A5003772441 @default.
• W2414893599 hasAuthorship W2414893599A5008127698 @default.
• W2414893599 hasAuthorship W2414893599A5017999352 @default.
• W2414893599 hasAuthorship W2414893599A5021958776 @default.
• W2414893599 hasAuthorship W2414893599A5024939717 @default.
• W2414893599 hasAuthorship W2414893599A5030587345 @default.
• W2414893599 hasAuthorship W2414893599A5039554579 @default.
• W2414893599 hasAuthorship W2414893599A5049404391 @default.
• W2414893599 hasAuthorship W2414893599A5060510665 @default.
• W2414893599 hasAuthorship W2414893599A5077450352 @default.
• W2414893599 hasAuthorship W2414893599A5084095032 @default.
• W2414893599 hasBestOaLocation W24148935991 @default.
• W2414893599 hasConcept C121608353 @default.
• W2414893599 hasConcept C126322002 @default.
• W2414893599 hasConcept C142724271 @default.
• W2414893599 hasConcept C2778087573 @default.
• W2414893599 hasConcept C2779438470 @default.
• W2414893599 hasConcept C2781156865 @default.
• W2414893599 hasConcept C71924100 @default.
• W2414893599 hasConceptScore W2414893599C121608353 @default.
• W2414893599 hasConceptScore W2414893599C126322002 @default.
• W2414893599 hasConceptScore W2414893599C142724271 @default.
• W2414893599 hasConceptScore W2414893599C2778087573 @default.
• W2414893599 hasConceptScore W2414893599C2779438470 @default.
• W2414893599 hasConceptScore W2414893599C2781156865 @default.
• W2414893599 hasConceptScore W2414893599C71924100 @default.
• W2414893599 hasLocation W24148935991 @default.
• W2414893599 hasOpenAccess W2414893599 @default.
• W2414893599 hasPrimaryLocation W24148935991 @default.
• W2414893599 hasRelatedWork W122825480 @default.
• W2414893599 hasRelatedWork W1984004483 @default.
• W2414893599 hasRelatedWork W2013131705 @default.
• W2414893599 hasRelatedWork W2031990193 @default.
• W2414893599 hasRelatedWork W2082669552 @default.
• W2414893599 hasRelatedWork W2112805850 @default.
• W2414893599 hasRelatedWork W2152727128 @default.
• W2414893599 hasRelatedWork W2349096397 @default.
• W2414893599 hasRelatedWork W3022751207 @default.
• W2414893599 hasRelatedWork W1929462032 @default.
• W2414893599 hasVolume "26" @default.
• W2414893599 isParatext "false" @default.
• W2414893599 isRetracted "false" @default.
• W2414893599 magId "2414893599" @default.
• W2414893599 workType "article" @default.